Because of its anti-coagulant drug, FXI, Mad Money's Jim Cramer thinks Isis Pharmaceuticals can climb much higher.» Read More
A new class of drugs which aim to lower levels of LDL are being pursued by multiple pharma companies and it could be a $10 billion market. Leonard Schleifer, Regeneron CEO, discusses what is known about bad cholesterol, and competition in the space.
While biotechnology shares are not cheap, they are nowhere near "bubble-like" valuations, says Bill Stone, Chief Investment Strategist at PNC Asset Management Group.
CNBC's Meg Tirrell breaks down the mega deal between Swiss pharmaceutical firm Roche and InterMune for $8.3 billion.
Switzerland's Roche is buying InterMune for $8.3 billion. CNBC's Meg Tirrell reports InterMune's Esbriet drug could draw more than $1 billion in annual revenue.
Drug giant Roche is buying biotech firm InterMune for $8.3 billion. CNBC's Jim Cramer discusses the lifesaving drug behind the wave of M&A deals.
CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."
Aug 19- The U.S. government has extended a contract with Cytori Therapeutics to develop a cell-derived treatment for burns, the company said on Tuesday. The government's Biomedical Advanced Research and Development Authority will provide up to $20.4 million to fund early development and costs associated with a clinical trial.
CNBC's Meg Tirrell reports which biotech drug developments investors are excited about.
Zafgen CEO Tom Hughes discusses the company's dedication to tackle obesity, with CNBC's Meg Tirrell. Hughes says the new drug works to impact the way the body handles fat.
CNBC's Morgan Brennan runs through today's big biotech movers.
Barbara Ryan, FTI Consulting, discusses the tremendous amount of innovation within in the biotech sector and why the segment is attractive.
CNBC's Meg Tirrell looks at companies in the early stages of Ebola drug and vaccine trials.
CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.
"The market is very favorable for biotech these days," says Les Funtleyder, Bluecloud Healthcare, in discussing growth in the space.
CNBC's Meg Tirrell speaks to Dr. George Scangos, Biogen Idec CEO, about the company's Q2 earnings surge, drug pipeline, and America's tax code. Scangos says we need a corporate tax rate that is competitive with rest of the world and a territorial tax system.
CNBC's David Faber reports Puma Biotechnology surges on positive results for a breast cancer drug.
Mark Schoenbaum, ISI Group, explains why his views differ from Janet Yellen on whether the biotech sector is forming a bubble.
Dodge Dorland, Chairman & Chief Investment Officer at Landor & Fuest Capital Managers, says social media and biotech stocks may see more downside in the short run.
After Janet Yellen's comments on stretched valuations in the social media and biotech sectors, CNBC's Seema Mody looks at what stocks are taking the biggest hit.
CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.